Loading...
Market
Story
FDA Grants Accelerated Approval to EPKINLY®, First Bispecific Antibody for Relapsed/Refractory Follicular Lymphoma
Jun 26, 2024, 11:38 PM
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Epcoritamab, marketed as EPKINLY®, for the treatment of relapsed or refractory follicular lymphoma (R/R FL). This approval marks the second for EPKINLY® and makes it the first bispecific antibody approved for both R/R FL and relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in the U.S. The drug is developed by AbbVie and Genmab, trading under the stock symbols $ABBV and $GMAB respectively. The approval has been highlighted in the #lymsm and #oncology communities.
View original story
Similar markets
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Below 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
Above 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%